Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Xoma Royalty Corporation (NQ: XOMA )

31.14 +0.28 (+0.91%)
Streaming Delayed Price Updated: 3:10 PM EST, Nov 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Xoma Royalty Corporation

< Previous 1 2 Next >
XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q2 2024
XOMA stock results show that XOMA missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
FDA Convenes Expert Panel Meeting For Zevra Therapeutics' Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base
FDA's Genetic Metabolic Diseases Advisory Committee will review Zevra Therapeutics' arimoclomol for Niemann-Pick disease type C on August 2. PDUFA decision expected by September 21. 
Via Benzinga
Exposures Product Safety
Demystifying XOMA: Insights From 5 Analyst Reviews
Via Benzinga
3 Crazy Good Stocks to Buy With $500 Right Now
For investors with only a little money to spare, these three supercharged stocks represent an outrageous opportunity for future growth. 
Via InvestorPlace
Peeling Back The Layers: Exploring XOMA Through Analyst Insights
Via Benzinga
XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q1 2024
XOMA stock results show that XOMA missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Cracking The Code: Understanding Analyst Reviews For XOMA
Via Benzinga
Recap: XOMA Q4 Earnings
Via Benzinga
XOMA's Return On Capital Employed Insights
Via Benzinga
XOMA Stock Earnings: XOMA Misses EPS, Misses Revenue for Q4 2023
XOMA stock results show that XOMA missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Biotech Royalty Aggregator XOMA To Acquire Small Cancer-Drug Developer Kinnate Biopharma
XOMA acquires Kinnate Biopharma for $2.3352 per share, with potential additional cash. The acquisition is expected to close in April 2024. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  On Friday, 57 companies reached new 52-week lows. 
Via Benzinga
XOMA Earnings Perspective: Return On Capital Employed
Via Benzinga
XOMA's Return On Capital Employed Insights
Via Benzinga
Starbucks And 3 Other Stock Insiders Are Buying
Although US stocks closed lower on Friday, there were a few notable insider trades. 
Via Benzinga
Recap: XOMA Q4 Earnings
XOMA (NASDAQ:XOMA) reported its Q4 earnings results on Tuesday, March 8, 2022 at 07:30 AM. Here's what investors need to know about the announcement. Earnings XOMA... 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  During Monday, 102 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  During Thursday, 56 stocks hit new 52-week lows. 
Via Benzinga
Arimoclomol and Aldoxorubicin Acquisition to Bolster XOMA's Revenue Growth: Analyst
Earlier today, XOMA Corporation (NASDAQ: XOMA) acquired the royalty and milestone rights associated with two assets from LadRx Corporation: arimoclomol for Niemann-Pick disease type C, and... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  Wednesday saw 59 companies set new 52-week lows. 
Via Benzinga
Recap: XOMA Q1 Earnings
XOMA (NASDAQ:XOMA) reported its Q1 earnings results on Tuesday, May 9, 2023 at 07:30 AM. Here's what investors need to know about the announcement. Earnings XOMA missed estimated earnings by 96.0%,... 
Via Benzinga
XOMA: Q1 Earnings Insights
XOMA (NASDAQ:XOMA) reported its Q1 earnings results on Tuesday, May 9, 2023 at 07:30 AM. Here's what investors need to know about the announcement. Earnings XOMA missed estimated earnings by 96.0%,... 
Via Benzinga
XOMA: Q3 Earnings Insights
XOMA (NASDAQ:XOMA) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:45 AM. Here's what investors need to know about the announcement. Earnings XOMA missed estimated earnings by... 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 168 companies reached new 52-week lows. 
Via Benzinga
XOMA Earnings Perspective: Return On Capital Employed
Benzinga Pro data, XOMA (NASDAQ:XOMA) reported Q1 sales of $3.11 million. Earnings fell to a loss of $2.28 million, resulting in a 107.64% decrease from last quarter. In Q4, XOMA earned $29.84 million,... 
Via Benzinga
XOMA's Return On Capital Employed Insights
According to Benzinga Pro, during Q4, XOMA (NASDAQ:XOMA) earned $29.84 million, a 772.77% increase from the preceding quarter. XOMA also posted a total of $35.94 million in sales... 
Via Benzinga
50 Biggest Movers From Yesterday
Gainers Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) shares surged 63.7% to settle at $2.21 on Wednesday after the company announced that in preclinical studies its lead... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's trading, 435 companies set new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Lixte Biotech Holdings (NASDAQ:LIXT) stock increased by 70.4% to $2.3 during Wednesday's regular session. Trading volume for this security as of 12:31 EST is... 
Via Benzinga
XOMA's Return On Capital Employed Overview
Benzinga Pro data, XOMA (NASDAQ:XOMA) reported Q3 sales of $940.00 thousand. Earnings fell to a loss of $3.35 million, resulting in a 9.17% decrease from last quarter. In Q2,... 
Via Benzinga
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.